Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) on Monday, plunged -6.52% from the previous trading day, before settling in for the closing price of $19.03. Within the past 52 weeks, CNTA’s price has moved between $7.38 and $19.09.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 2.97%. With a float of $90.14 million, this company’s outstanding shares have now reached $131.66 million.
Considering the fact that the conglomerate employs 76 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 89.52%, operating margin of -2342.65%, and the pretax margin is -2294.59%.
Centessa Pharmaceuticals plc ADR (CNTA) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Centessa Pharmaceuticals plc ADR is 31.53%, while institutional ownership is 51.01%. The most recent insider transaction that took place on Feb 07 ’25, was worth 580,797. In this transaction Chief People Officer of this company sold 30,526 shares at a rate of $19.03, taking the stock ownership to the 54,322 shares. Before that another transaction happened on Feb 10 ’25, when Company’s Chief People Officer sold 429 for $18.99, making the entire transaction worth $8,147. This insider now owns 54,322 shares in total.
Centessa Pharmaceuticals plc ADR (CNTA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.37 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.97% per share during the next fiscal year.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Trading Performance Indicators
Centessa Pharmaceuticals plc ADR (CNTA) is currently performing well based on its current performance indicators. A quick ratio of 21.52 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 338.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.55 in one year’s time.
Technical Analysis of Centessa Pharmaceuticals plc ADR (CNTA)
Compared to the last year’s volume of 0.7 million, its volume of 1.12 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 83.27%. Additionally, its Average True Range was 1.19.
During the past 100 days, Centessa Pharmaceuticals plc ADR’s (CNTA) raw stochastic average was set at 72.04%, which indicates a significant increase from 63.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.51% in the past 14 days, which was lower than the 55.35% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.88, while its 200-day Moving Average is $13.44. Nevertheless, the first resistance level for the watch stands at $18.90 in the near term. At $20.02, the stock is likely to face the second major resistance level. The third major resistance level sits at $21.04. If the price goes on to break the first support level at $16.76, it is likely to go to the next support level at $15.74. Should the price break the second support level, the third support level stands at $14.62.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Key Stats
Market capitalization of the company is 2.34 billion based on 131,845K outstanding shares. Right now, sales total 6,850 K and income totals -151,090 K. The company made 0 K in profit during its latest quarter, and -42,570 K in sales during its previous quarter.
